Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Core Viewpoint - Dupixent (dupilumab) is recommended for approval by the European Medicines Agency for treating chronic spontaneous urticaria (CSU) in children aged 2 to 11 years who have not responded adequately to standard antihistamine treatment [1][2]. Group 1: Product Approval and Clinical Trials - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent for children aged 2 to 11 years with moderate-to-severe CSU [1]. - The recommendation is based on data from the LIBERTY-CUPID clinical trial program, which includes two Phase 3 trials and a single-arm Phase 3 trial specifically for children aged 2 to 11 years [2]. - In the U.S., a supplemental Biologics License Application (sBLA) for Dupixent in children aged 2 to 11 years with CSU has been accepted for review, with a decision expected by April 2026 [3]. Group 2: Disease Background and Treatment Options - Chronic spontaneous urticaria (CSU) is a chronic skin disease characterized by type 2 inflammation, leading to debilitating hives and itching, often inadequately controlled by standard antihistamine treatments [5]. - Many patients with CSU experience uncontrolled symptoms despite treatment, leaving them with limited alternative options [5]. Group 3: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways, which are key drivers of type 2 inflammation [6]. - The drug has received regulatory approvals in over 60 countries for various indications, including CSU, and is currently being used by more than 1,400,000 patients globally [7][10]. - Dupixent is developed using Regeneron's VelocImmune technology, which allows for the creation of optimized fully human antibodies [8]. Group 4: Ongoing Research and Future Indications - Regeneron and Sanofi are conducting studies on Dupixent for additional diseases driven by type 2 inflammation, including chronic pruritus of unknown origin and lichen simplex chronicus [11]. - The Dupixent development program has involved over 60 clinical trials with more than 12,000 patients across various chronic diseases [10].